CN Patent

CN117731654B — Jjh201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途

Assigned to Jiangsu Jibeier Pharmaceutical Co ltd · Expires 2024-05-07 · 2y expired

What this patent protects

本发明公开了JJH201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途，本发明首次发现JJH201601能够显著抑制初发性脑胶质瘤细胞系和复发性脑胶质瘤细胞系的生长，具有良好的开发成初发性脑胶质瘤和复发性脑胶质瘤治疗药物的潜能，为脑胶质瘤治疗药物开发这一领域提供了全新的思路和策略，具有良好的临床应用前景。

USPTO Abstract

本发明公开了JJH201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途，本发明首次发现JJH201601能够显著抑制初发性脑胶质瘤细胞系和复发性脑胶质瘤细胞系的生长，具有良好的开发成初发性脑胶质瘤和复发性脑胶质瘤治疗药物的潜能，为脑胶质瘤治疗药物开发这一领域提供了全新的思路和策略，具有良好的临床应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN117731654B
Jurisdiction
CN
Classification
—
Expires
2024-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Jibeier Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.